Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
C 21.63 2.22% 0.47
MYGN closed up 2.22 percent on Monday, March 18, 2024, on approximately normal volume. It ran into resistance at its 50 day moving average.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Outside Day Range Expansion 0.00%
50 DMA Resistance Bearish 2.22%
Volume Surge Other 2.22%
Down 3 Days in a Row Weakness 2.22%
Down 4 Days in a Row Weakness 2.22%
Down 5 Days in a Row Weakness 2.22%
Fell Below 50 DMA Bearish 1.45%
MACD Bearish Centerline Cross Bearish 1.45%
NR7 Range Contraction 1.45%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 9 hours ago
Rose Above Previous Day's High about 9 hours ago
Outside Day about 9 hours ago
Down 1% about 10 hours ago
Rose Above 50 DMA about 12 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Myriad Genetics, Inc. Description

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Genetics Prostate Cancer Medical Genetics Ovarian Cancer Melanoma Pancreatic Cancer Biomarkers Colorectal Cancer Lab Testing Medical Research Diagnostic Tests Diagnostic Services Immunoassay Personalized Medicine Chemical Pathology Companion Diagnostic Breast And Ovarian Cancer Whole Blood Medical Signs Uterine Cancer

Is MYGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.21
52 Week Low 13.82
Average Volume 653,283
200-Day Moving Average 19.55
50-Day Moving Average 21.63
20-Day Moving Average 22.29
10-Day Moving Average 22.04
Average True Range 1.07
RSI (14) 47.09
ADX 21.11
+DI 14.21
-DI 21.56
Chandelier Exit (Long, 3 ATRs) 20.54
Chandelier Exit (Short, 3 ATRs) 23.79
Upper Bollinger Bands 23.81
Lower Bollinger Band 20.76
Percent B (%b) 0.28
BandWidth 13.68
MACD Line -0.10
MACD Signal Line 0.09
MACD Histogram -0.1898
Fundamentals Value
Market Cap 1.94 Billion
Num Shares 89.6 Million
EPS -3.36
Price-to-Earnings (P/E) Ratio -6.44
Price-to-Sales 2.72
Price-to-Book 2.89
PEG Ratio 1.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.86
Resistance 3 (R3) 22.75 22.23 22.65
Resistance 2 (R2) 22.23 21.92 22.28 22.58
Resistance 1 (R1) 21.93 21.72 22.08 22.04 22.52
Pivot Point 21.41 21.41 21.49 21.47 21.41
Support 1 (S1) 21.11 21.10 21.26 21.22 20.74
Support 2 (S2) 20.59 20.91 20.65 20.68
Support 3 (S3) 20.29 20.59 20.61
Support 4 (S4) 20.40